Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03241810
Title Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Merrimack Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.